Evicenter
P&T meetings

Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer
Exelixis
Regulatory submission
NDA submitted December 2025
Launch
Not announced
Last updated
65 sources

Company-reported prevalence

Zanzalintinib

Overview

FieldValue
DrugZanzalintinib (XL092)
IndicationMetastatic colorectal cancer
DiseaseColorectal cancer (CRC) and metastatic colorectal cancer (mCRC)
CompanyExelixis, Inc.
Documents searchedCorporate website: home, Clinical Trials & Pipeline, Treating Cancer, Medicines, and Development pages (accessed October 2026); press releases of January 25, 2025, June 22, 2025, October 20, 2025, February 2, 2026, May 19, 2026, June 22, 2026, and August 5, 2026; Form 10-K for fiscal year 2025 (February 10, 2026); Form 10-Q for the first quarter of 2026 (May 2026); Form 10-Q for the second quarter of 2026 (August 2026); first quarter 2026 earnings presentation (May 5, 2026); second quarter 2026 earnings presentation (August 5, 2026); STELLAR-303 healthcare professional brochure (2023)
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Incidence (all colorectal cancer stages): Exelixis press release, June 2026

“Approximately 159,000 new cases will be diagnosed in the U.S. in 2026, with around 55,000 expected deaths from the disease.” (opens the source at this quote in a new tab)

Cited source: 2.1 American Cancer Society 2026

Exelixis (2026) press release, June 22, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence (all colorectal cancer stages): Exelixis Form 10-K for 2025, February 2026

“According to the American Cancer Society, in 2026, approximately 159,000 new cases will be diagnosed in the U.S. with around 55,000 expected deaths from the disease.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Exelixis (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Incidence (all colorectal cancer stages): Exelixis press release, October 2025

“Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025.” (opens the source at this quote in a new tab)

Cited source: 2.2 American Cancer Society 2025

Exelixis (2025) press release, October 20, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number treated (third-line or later metastatic colorectal cancer): Exelixis second quarter 2026 earnings presentation, August 2026

“2026: 3L+ mCRC Market Breakdown (U.S.)”

“~23,000 Patients” (opens the source at this quote in a new tab)

Cited source: 2.4 Exelixis 2025

Exelixis (2026) second quarter 2026 earnings presentation, August 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 19 of 44 (opens in a new tab)

Europe

No evidence found.

Global

No evidence found.

Other countries and regions

No evidence found.

Geography not stated

Prevalence (share of colorectal cancer cases diagnosed at the metastatic stage): Exelixis press release, June 2026

“Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is around just 15%.” (opens the source at this quote in a new tab)

Cited source: 2.1 American Cancer Society 2026; 2.3 National Cancer Institute 2026

Exelixis (2026) press release, June 22, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Prevalence (share of colorectal cancer cases diagnosed at the metastatic stage): Exelixis Form 10-K for 2025, February 2026

“Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is around just 15%.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Exelixis (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Prevalence (share of metastatic colorectal cancer with a RAS mutation): Exelixis Form 10-K for 2025, February 2026

“It has been estimated that approximately 40-52% of metastatic CRC cases exhibit a RAS mutation.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Exelixis (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Sources the company cites

American cancer society 2026

Reference as the company lists it

“Cancer Facts & Figures 2026. ACS website. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf. Accessed June 2026.” (opens the source at this quote in a new tab)

Exelixis (2026) press release, June 22, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“In 2026, an estimated 108,860 cases of colon cancer and 49,990 cases of rectal cancer will be diagnosed in the US, and 55,230 people will die from these cancers (Table 1).” (opens the source at this quote in a new tab)

American Cancer Society (2026) Cancer Facts & Figures 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 15 of 48 (opens in a new tab)

American cancer society 2025

Reference as the company lists it

“Key Statistics for Colorectal Cancer. ACS website. Available at: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html. Accessed October 2025.” (opens the source at this quote in a new tab)

Exelixis (2025) press release, October 20, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the nearest figure

“The American Cancer Society’s estimates for the number of colorectal cancers in the United States for 2026 are:”

“About 108,860 new cases of colon cancer (55,410 in men and 53,450 in women)”

“About 49,990 new cases of rectal cancer (28,750 in men and 21,240 in women)” (opens the source at this quote in a new tab)

American Cancer Society (2026) Key Statistics for Colorectal Cancer, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

National cancer institute 2026

Reference as the company lists it

“Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: https://seer.cancer.gov/statfacts/html/colorect.html. Accessed June 2026.” (opens the source at this quote in a new tab)

Exelixis (2026) press release, June 22, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“Distant Cancer Has Metastasized 23%” (opens the source at this quote in a new tab)

Exelixis 2025

Reference as the company lists it

“Sources: (1) Exelixis Internal Market Research (2025)” (opens the source at this quote in a new tab)

Exelixis (2026) second quarter 2026 earnings presentation, August 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 19 of 44 (opens in a new tab)

Passage carrying the figure

Not quoted: Internal company market research; no published document or address is named.

References

  1. American Cancer Society (2026) Cancer Facts & Figures 2026 (opens in a new tab)
  2. American Cancer Society (2026) Key Statistics for Colorectal Cancer (opens in a new tab)
  3. Exelixis (2025) press release, October 20, 2025 (opens in a new tab)
  4. Exelixis (2026) Form 10-K for 2025 (opens in a new tab)
  5. Exelixis (2026) press release, June 22, 2026 (opens in a new tab)
  6. Exelixis (2026) second quarter 2026 earnings presentation, August 2026 (opens in a new tab)
  7. National Cancer Institute (2026) SEER Cancer Stat Facts: Colorectal Cancer (opens in a new tab)